Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Work begins on bird flu vaccine


CSIRO Livestock Industries and animal health company, Imugene Limited, have started research work designed to develop a vaccine for chickens at risk of contracting the deadly strain of avian influenza now causing havoc in Asia.

The research team aims to deliver a trial vaccine against the virulent H5N1 strain of the disease, within a matter of months. Once developed, the vaccine could be used to safeguard Australia’s poultry industry.

CSIRO’s Dr Chris Prideaux says that even if development of a vaccine is too late to help control the current outbreak in Asia, it would still be possible for researchers to quickly adapt it to deal with new strains of avian influenza.

"In this way, if we are successful in creating a more effective vaccine, this would then provide a new option for controlling avian influenza outbreaks if and when they arise, either in Australia or overseas," he says.

The research will utilise Imugene’s Adenoviral Vector Delivery System (AVDS) - which originated from CSIRO research - to deliver a small portion of the flu genetic material to poultry to stimulate the birds’ immune response and provide protection from the flu virus.

Imugene’s Managing Director, Dr Warwick Lamb, says the platform AVDS allows a new potential vaccine to be constructed quickly at CSIRO’s Australian Animal Health Laboratory (AAHL) in Geelong - one of the world’s leading animal disease diagnosis and research facilities.

"The CSIRO research team have been working with the AVDS and its use with poultry for over a decade and have relevant experience with chicken viruses," Dr Lamb says.

"Vaccines based on the AVDS only use a portion of the viral structure of the flu virus, making them safer than a live attenuated vaccine approach. With the latter approach, there is some risk that the vaccine could mutate or combine with naturally occurring influenza virus, resulting in potential new strains that are not covered by the existing vaccines. The AVDS vaccine would avoid this problem."

However, because different vaccines are required for each strain of the influenza virus, a new AVDS vaccine would only be effective against the strain of the virus (H5N1) it is designed to target.


Imugene Limited (ASX Code: IMU) is an Australian biopharmaceutical company specialising in the development and commercialisation of animal health products for production animals (pigs and poultry) and companion (pet) animals.

Imugene’s products safely prevent disease and parasites in animals, reduce or eliminate the use of antibiotics, harmful chemicals and drugs and, in production animals, reduce the level of antibiotic and chemical residue entering the human food chain.

Imugene owns the worldwide rights to the Adenoviral Vector Delivery System for pigs and poultry. Patents have been either granted or are under application in the major pig and poultry markets worldwide.

Imugene’s poultry and pig portfolio is tapping into segments worth US$3 billion of the existing US$8 billion global spend on existing treatments per year. The majority of the existing treatments are chemical and antibiotic solutions that are becoming less effective for disease treatment and productivity enhancement. Compounding the problem of diminishing efficacy, governments and health organisations, internationally, are lobbying and legislating against the use of antibiotics in favour of non-chemical treatments.

More information:

Mr Graham Dowland, Imugene’s Executive Chairman, +61 8 9322 9189
Dr Warwick Lamb, Imugene’s Managing Director, +61 2 9870 7330
Dr Chris Prideaux, CSIRO Livestock Industries, + 61 3 5227 5791

Media assistance:
Emma Homes, CSIRO Livestock Industries, + 61 3 5227 5123, 0409 236 152

Bill Stephens | CSIRO
Further information:

More articles from Agricultural and Forestry Science:

nachricht “How trees coexist” – new findings from biodiversity research published in Nature Communications
22.03.2018 | Technische Universität Dresden

nachricht Earlier flowering of modern winter wheat cultivars
20.03.2018 | Georg-August-Universität Göttingen

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Modular safety concept increases flexibility in plant conversion

22.03.2018 | Trade Fair News

New interactive map shows climate change everywhere in world

22.03.2018 | Earth Sciences

New technologies and computing power to help strengthen population data

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>